These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 9884282)
41. Lack of correlation between IgG T-lymphocyte flow cytometric crossmatches with primary renal allograft outcome. Evans PR; Lane AC; Lambert CM; Reynolds WM; Wilson PJ; Harris KR; Slapak M; Lee HA; Smith JL Transpl Int; 1992; 5 Suppl 1():S609-12. PubMed ID: 14621889 [TBL] [Abstract][Full Text] [Related]
42. Clinical significance of a positive flow crossmatch on the outcomes of cadaveric renal transplants. Ilham MA; Winkler S; Coates E; Rizzello A; Rees TJ; Asderakis A Transplant Proc; 2008; 40(6):1839-43. PubMed ID: 18675065 [TBL] [Abstract][Full Text] [Related]
43. Absence of irreversible rejection in the presence of warm anti-donor-HLA class I cytotoxic IgG antibody. Shoker A; Klassen J; Herbut B Clin Nephrol; 1997 Feb; 47(2):87-91. PubMed ID: 9049455 [TBL] [Abstract][Full Text] [Related]
44. General insufficiency of the classical CDC-based crossmatch to detect donor-specific anti-HLA antibodies leading to invalid results under recipients' medical treatment or underlying diseases. Schlaf G; Mauz-Körholz C; Ott U; Leike S; Altermann W Histol Histopathol; 2012 Jan; 27(1):31-8. PubMed ID: 22127594 [TBL] [Abstract][Full Text] [Related]
45. Sensitivity, specificity and clinical relevance of different cross-matching assays in deceased-donor renal transplantation. Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Hallar M; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N Transpl Immunol; 2008 Nov; 20(1-2):61-7. PubMed ID: 18929659 [TBL] [Abstract][Full Text] [Related]
46. Red cell antibodies resulting in false-positive complement-dependent cytotoxicity cross-match: A unique case. Sawant RB; Sheth S; Mehta P; Naker D Asian J Transfus Sci; 2021; 15(1):94-96. PubMed ID: 34349465 [TBL] [Abstract][Full Text] [Related]
47. Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Bryan CF; Baier KA; Nelson PW; Luger AM; Martinez J; Pierce GE; Ross G; Shield CF; Warady BA; Aeder MI; Helling TS; Muruve N Transplantation; 1998 Dec; 66(12):1827-32. PubMed ID: 9884283 [TBL] [Abstract][Full Text] [Related]
48. Simultaneous detection of antibody binding and cytotoxicity in flow cytometry crossmatch for renal transplantation. Won DI; Jeong HD; Kim YL; Suh JS Cytometry B Clin Cytom; 2006 Mar; 70(2):82-90. PubMed ID: 16470535 [TBL] [Abstract][Full Text] [Related]
49. Pre-transplant donor specific antibody and its clinical significance in kidney transplantation. Thammanichanond D; Ingsathit A; Mongkolsuk T; Rattanasiri S; Kantachuvesiri S; Sakhonrat C; Leenanupan C; Worawichawongs S; Kitpoka P Asian Pac J Allergy Immunol; 2012 Mar; 30(1):48-54. PubMed ID: 22523907 [TBL] [Abstract][Full Text] [Related]
50. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767 [TBL] [Abstract][Full Text] [Related]
51. Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations. Amico P; Hirt-Minkowski P; Hönger G; Gürke L; Mihatsch MJ; Steiger J; Hopfer H; Schaub S Transpl Int; 2011 Jun; 24(6):560-9. PubMed ID: 21332582 [TBL] [Abstract][Full Text] [Related]
52. The presence of donor-specific human leukocyte antigen antibodies does not preclude successful withdrawal of tacrolimus in stable renal transplant recipients. Kreijveld E; Hilbrands LB; van Berkel Y; Joosten I; Allebes W Transplantation; 2007 Nov; 84(9):1092-6. PubMed ID: 17998862 [TBL] [Abstract][Full Text] [Related]
53. Modified flow cytometry crossmatch detecting alloantibody-related cytotoxicity as a way to distinguish lytic antibodies from harmless in allosensitised kidney recipients. Zieliński M; Zielińska H; Moszkowska G; Dȩbska-Ślizień A; Rutkowski B; Trzonkowski P Transplant Proc; 2013; 45(1):88-94. PubMed ID: 23375279 [TBL] [Abstract][Full Text] [Related]
55. Solid phase-based cross-matching as solution for kidney allograft recipients pretreated with therapeutic antibodies. Schlaf G; Apel S; Wahle A; Altermann WW Biomed Res Int; 2015; 2015():587158. PubMed ID: 25654115 [TBL] [Abstract][Full Text] [Related]
56. Comparative analysis of two methods to detect donor-specific anti-HLA antibodies after kidney transplant. Gil BC; Kulzer ASS; de Moraes P; Toresan R; da Rosa Vicari A; Dos Santos Fagundes I; Merzoni J; Ewald GM; Cardone JM; Silva FG; Manfro RC; Jobim LF Transpl Immunol; 2018 Aug; 49():7-11. PubMed ID: 29577967 [TBL] [Abstract][Full Text] [Related]
57. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates. Arnold ML; Dechant M; Doxiadis II; Spriewald BM Tissue Antigens; 2008 Jul; 72(1):60-6. PubMed ID: 18588575 [TBL] [Abstract][Full Text] [Related]
58. Clinical relevance of preformed IgG and IgM antibodies against donor endothelial progenitor cells in recipients of living donor kidney grafts. Daniel V; Sadeghi M; Suesal C; Scherer S; Tran H; Gombos P; Trojan K; Morath C; Opelz G Clin Transplant; 2016 Feb; 30(2):124-30. PubMed ID: 26537026 [TBL] [Abstract][Full Text] [Related]